Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Leqembi lecanemab Alzheimer’s disease Active
Leqvio inclisiran Primary hypercholesterolemia Do not reimburse Active
Leqvio inclisiran Primary hypercholesterolemia Reimburse with clinical criteria and/or conditions Active
Leqvio inclisiran Primary hypercholesterolemia Do not reimburse Complete
Levemir Insulin detemir Diabetes mellitus Do not list Complete
Levemir Insulin detemir Diabetes mellitus Withdrawn
Levemir Insulin detemir Diabetes mellitus Do not list Complete
Levemir Insulin detemir Diabetes mellitus Type1, Pediatrics Do not list Complete
Libtayo Cemiplimab Advanced Cutaneous Squamous Cell Carcinoma (CSCC) Reimburse with clinical criteria and/or conditions Complete
Libtayo cemiplimab Basal cell carcinoma Reimburse with clinical criteria and/or conditions Complete
Libtayo cemiplimab Non-small cell lung cancer Reimburse with clinical criteria and/or conditions Complete
Libtayo cemiplimab Locally advanced or metastatic NSCLC (first line) Reimburse with clinical criteria and/or conditions Complete
Livmarli maralixibat Alagille syndrome Reimburse with clinical criteria and/or conditions Complete
Livtencity maribavir Post-transplant cytomegalovirus infection Reimburse with clinical criteria and/or conditions Complete
Lixiana NVAF Edoxaban Nonvalvular atrial fibrillation, prevention of stroke and systemic embolism. Reimburse with clinical criteria and/or conditions Complete
Lixiana VTE Edoxaban Venous thromboembolism, treatment and recurrence prevention. Reimburse with clinical criteria and/or conditions Complete
Lodalis Colesevelam hydrochloride Hypercholesterolemia Do not list at the submitted price Complete
Lokelma sodium zirconium cyclosilicate Hyperkalemia, adults Do not reimburse Complete
Lonsurf Trifluridine and Tipiracil Metastatic Colorectal Cancer Do not reimburse Complete
Lonsurf Trifluridine and Tipiracil mCRC Resubmission Do not reimburse Complete
Lonsurf Trifluridine-Tipiracil Gastric Cancer Reimburse with clinical criteria and/or conditions Complete
Lonsurf trifluridine and tipiracil Metastatic colorectal cancer Reimburse with clinical criteria and/or conditions Complete
Lorbrena Lorlatinib Non-Small Cell Lung Cancer (NSCLC) Do not reimburse Complete
Lorbrena lorlatinib ALK-positive locally advanced or metastatic non-small cell lung Reimburse with clinical criteria and/or conditions Complete
Lotemax Loteprednol etabonate Post-operative inflammation following cataract surgery Do not list Complete